eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
Portal dla gastroenterologów!
SCImago Journal & Country Rank
vol. 13
Poleć ten artykuł:
Artykuł oryginalny

Effectiveness of Helicobacter pylori eradication established on the basis of examination of antibiotic resistance of the bacteria

Aleksander Szadkowski
Magdalena Zemlak
Jacek Muszyński

Data publikacji online: 2018/05/16
Plik artykułu:
- effectiveness.pdf  [0.09 MB]
Pobierz cytowanie
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero


Helicobacter pylori (HP) infection belongs to the infections most common in the human population. According to World health Organization (WHO) estimates, HP infection affects approximately 70% of inhabitants of developing countries and approximately 30% of developed countries – ranging from 15% to over 95% in countries where the infection affects the majority of the population [1]. The incidence of the infection in Poland, in people over 60 years old, is as high as 90% [2, 3]. The treatment is provided by numerous medical specialties. The efficacy of eradication is assessed as ranging broadly from 65% to 94% of cases; Szadkowski et al. [4] reported 65%, Gispert et al. [5] reported 90.5%, and Muszyński et al. reported 94% [6].
A meta-analysis of 32 studies (4727 patients) found the mean cure from the infection with the help of a triple therapy to be achieved in 80% of patients [7].
The treatment of HP infection tends to be empirical despite a high number of failures (over 20%) [8, 9]. The efficacy of eradication therapies is declining, reaching in some countries 60%, which correlates inversely with the growing drug resistance of the bacteria [10]. This resulted in the Maastricht recommendations, which suggest the performance, in high HP clarithromycin resistance regions, of an antibiogram prior to the commencement of the treatment [11]. In Poland, resistance to clarithromycin reaches 29% while to metronidazole it is 40% [12]. In patients in whom cure was not obtained during the first- or second-line therapy, secondary resistance to the recommended antibiotics may develop with selection of resistant strains [13]. It is thus logical to institute another treatment, provided it is absolutely necessary, after the examination of the antibiotic resistance of the bacteria.
Given the frequent inefficacy of the hitherto proposed schemes of treatment of HP infection, an attempt was made to assess the efficacy of a therapy based on the antibiotic resistance of cultured bacteria. The study covered patients from one region of Poland (Płock and Mazowieckie Voivodeship) in the years 2005–2015.


Evaluation of the efficacy of the eradication of HP infection, conducted in an out-patient course, in patients with a history of at least two inefficacious eradication treatments. Analysis of factors of possible contribution to the inefficacy of the HP eradication treatment based on the drug-susceptibility of the bacteria.

Material and methods

The study covered patients treated by the CM Medica Gastroenterology Outpatient Clinic in Płock (Orlen Medica until June 2014) in the period from January 2005 to December 2015.
The total material for bacteriological assessment was collected from 154 patients: 80 women and 74 men, reporting subsequently to the Clinic, who had previously been subject to HP eradication treatment at least two times. All the patients studied were referred for a check-up endoscopic examination of the upper segment of the digestive tract due to dyspepsia. A culture positive for HP infection was obtained in 59 patients (in three of them (5%) the urease test was negative). In one patient an antibiogram could not be performed due to abundant accompanying flora.
Finally, 58 patients were started on another eradication therapy (triple – antibiotic + metronidazole or two antibiotics in the case of confirmed resistance to metronidazole) in accordance with the HP susceptibility-to-antibiotics result. In addition, the therapy included a proton pump blocker in a standard dose of 2 × daily as well as a probiotic. Initially, a 7-day therapy was instituted, and in the following years a 10-day or sequential therapy. The treatment of HP was consistent with the Maastricht guidelines and Polish Society of Gastroenterology recommendations then in force [14, 15].
No side effects were observed that would require discontinuation of the pharmacological treatment. The efficacy of the HP treatment was assessed after 6–8 weeks from the termination of the treatment, with the use of the certified urease test Gold Hpdry by Lencomm (the reading was performed after 1 h, as recommended by the manufacturer, in patients undergoing a subsequent repeat gastroscopy or HP stool antigen test (SAT), Helicobacter Antigen Test by Hydrex Diagnosticx Ltd.). The stool test is recommended by American Gastroenterological Societies, American Gastroenterological Association (AGA) and American College Gastroenterology (ACG), as very accurate in terms of both recognition of HP infection and efficacy of eradication [16].
Bacteriological examination was performed in the Institute of Bacteriology of the Voivodeship Combined Hospital in Płock, in the anaerobic microorganism diagnostic laboratory. Biopsy specimens of gastric mucosa were placed on the Protragrem pylori transport substrate and then transferred (without selection) onto Columbia agar substrate and the same substrate with the addition of antibiotics. The identification was based on the determination of biochemical activity and a preparation from Gram-stained cultures. The drug-susceptibility of HP strains was assessed on Wilkins-Chalgren agar substrate in relation to the following antibiotics: amoxicillin, clarithromycin, tetracycline, rifampicin, levofloxacin, and metronidazole. The assessment of the drug susceptibility to individual antibiotics was extended in the following years of the applied treatment.
Evaluation was also made of the efficacy of eradication depending on age, sex, body mass index (BMI), and cigarette smoking, as well as the presence of a bile reflux to the stomach disclosed on gastroscopy. The presence of a bile reflux was defined as a very large quantity of liquid bile and dense bile in the gastric lake as well as visible bile precipitates on the gastric mucosa. For a period of at least 2 weeks prior to the performance of the tests, the patients did not take any proton pump inhibitors (PPIs) or antibiotics.

Statistical analysis

The results of the examinations were subjected to a statistical analysis; a standard error was calculated from the binomial distribution and the statistical significance with the use of Student’s t-test.


From among the 58 patients with a positive culture result, efficacious eradication control was achieved in 32 patients. In 11 patients the urease test was negative, while in 10 the stool test was negative. A positive urease test was reported in nine and a positive stool test in 2 patients.
The efficacy of the antibiogram-based treatment amounted to 65.62% (Table I).
Table II shows the development of resistance to individual antibiotics in the subsequent 5 years of observation.
The culture towards HP infection was positive in 59 patients, and the antibiogram was obtained for 58 patients. In one patient an antibiogram could not be performed due to abundant accompanying flora.
Table III presents the influence of age, sex, body mass, cigarette smoking, and the presence of bile reflux into the stomach on the efficacy of the treatment.


The hitherto applied therapeutic schemes of HP eradication are burdened with high inefficacy. As early as in 1997, Maastricht guidelines recommended that treatment efficacy of 80% be achieved, and according to the Kyoto consensus of 2015 it is advisable that only treatment schemes giving a chance of efficacious HP eradication in at least 90% be applied [17]. The 2014 Guidelines of the Polish Gastroenterological Society indicated the advisability of the control of the efficacy of eradication of the H. pylori, which should be performed with the use of non-invasive tests after a lapse of 4–6 weeks from the end of the treatment [14].
The urease test is recommended as an examination of first choice in the diagnostics of HP infection, but it is not recommended as an examination evaluating the efficacy of eradication, primarily due to the fact that it requires the performance of an endoscopy. What is recommended in the first place is the breath test, but the urease test or the stool test, applied in this study, are much more easily accessible in clinical practice and are devoid of false positive results [11].
The Maastricht V Consensus recommends, in patients with an at least twofold therapeutic failure and/or allergy to the antibiotic planned to be used, a repeat gastroscopy with biopsy with the purpose of performing a culture and assessment of HP susceptibility to antibiotics, whenever possible [18]. The value of the microbiological examination refers primarily to the determination of resistance to clarithromycin, levofloxacin, and metronidazole. Studies by Wenzhen et al. [19] as well as Sugimoto et al. [20] indicate that a therapy based on an antibiogram is more effective than a standard empirical therapy and, consequently, is more economical.
The results obtained in this study seem to indicate an unexpectedly low efficacy of HP eradication therapy based on an antibiogram, at just 65.62%.
Several earlier studies assessing the result of an antibiogram-based treatment also did not reveal its advantage over an empirical treatment in patients after the first unsuccessful therapeutic attempt [21]. Similarly, Miwa et al. [13] did not find differences in the percentage of successful eradications between groups treated on the basis of drug-susceptibility treatment and groups treated in a standard way.
This may be caused by a variety of factors. The latter may involve poor compliance, but the relatively small study group in this study was particularly motivated and monitored as regards their compliance with the rules of the treatment. Thus, other causes should be taken into account. It is known that a simultaneous infection with a few strains is possible, some in the antrum and others in the body of the stomach, strains of different susceptibility to antibiotics [22].
Other factors making eradication impossible include the presence of HP in the oral cavity – subgingival biofilm and dental plaque. Despite the infection having been cured in the stomach, approximately 60% of patients still have the same bacteria in the oral cavity, and it is these bacteria that may re-infest gastric mucosa [23].
Other factors that may influence the efficacy of the treatment may include multi-resistance of bacteria, infection with cagA [24] strains, low sensitivity of the culture, and cigarette smoking. An analysis of factors of potential contribution to the inefficacy of the treatment shows that sex, age, BMI, and the presence of a bile reflux into the stomach did not have an influence on the result of the applied eradication schemes.
The small size of the study group does not, however, allow us to determine non-ambiguous dependences. Nevertheless, a dependence was found for tobacco smoking, which decreased the efficacy of the eradication in a statistically significant way. This is consistent with the meta-analysis of 22 studies, which revealed that tobacco smoking increases the percentage of failed eradications by 8.4% [25]. One of the studies did not confirm the influence of tobacco smoking on the result of the HP infection treatment. The Polish study by Al-Medhagi et al. [26] did not confirm the influence of stimulants (tobacco smoking, coffee drinking, alcohol drinking) on the efficacy of eradication with the use of amoxicillin, metronidazole, or tinidazole and lansoprazole.
Persistent HP infection in some of the patients studied could not be a re-infection because the assessment was performed after a lapse of 6–8 weeks from the end of the treatment.
An eradication therapy based on drug-susceptibility is subject to numerous limitations. It requires endoscopy. It requires time. The culture is costly and the sensitivity is limited 80–90% [27]. And, first and foremost, this therapy is difficult to apply in practice.
The question is thus how to proceed in view of the low efficacy of the antibiogram-based eradication. The regional antibiotic resistance of HP should be monitored, quadruple therapies with bismuth in the first line mainly applied, the same treatment schemes never repeated, clarithromycin and also levofloxacin [28] avoided, and a 14-day treatment promoted as a new standard. Triple therapies with high doses of antibiotics have shown promising results but as yet without recommendations [29, 30].
Resistance to tetracycline and amoxicillin is rare – to tetracycline it is estimated at below 1%, to amoxicillin at 1–3% [29, 31].
Meanwhile, in this study a tendency towards a higher percentage resistance, reaching almost 1.3% for amoxicillin and almost 2.5% for tetracycline, was observed, and this was during the past 10 years of the duration of the study. This means that at present this percentage can be even higher and the resistance of HP to both these antibiotics, hitherto considered as very helpful and basic in the treatment of this infection, should be monitored.
Resistance to levofloxacin was examined only in a few cases, and drug resistance to it was not established. However, due to reports of high (over 30%) and fast-growing HP resistance to this chemotherapeutic agent, it should be avoided (the US Food and Drug Administration (FDA) approves safety labelling changes for fluoroquinolones) [32].
What can be considered after the failure of the first eradication treatment, if it is necessary to perform endoscopy, is the performance of a microbiological examination, in particular in regions where the chance of infection with antibiotic resistant strains is high [28].
On the other hand, if a therapy with bismuth and tetracycline, resistance to which is extremely low, is planned, resistance to metronidazole is of lesser importance [33]. Resistance to metronidazole is high but, according to experts, remains stable at 30–40% [11]. Meanwhile, in this study it exceeded 70%.
In turn, with doubled resistance to clarithromycin and metronidazole and the absence of a possibility to apply bismuth, what is left is a choice between levofloxacin, ribabutin, or therapy with high doses of amoxicillin (3 × 1000 mg/day).
It should be emphasised that the present Toronto guidelines do not recommend that probiotics be added to the HP eradication therapy to avoid side effects or to improve the efficacy of the treatment [31].


The study of the drug-resistance of HP does not increase the efficacy of the eradication therapy established on the basis of an antibiogram. In Polish patients resistance to clarithromycin and metronidazole of HP is high and becoming increasingly resistant; however, we found low bacterial resistance to tetracycline. Tobacco smoking decreases the efficacy of eradication in a statistically significant way.


This study was financed from the statutory funds of the Clinic.

Conflict of interest

The authors declare no conflict of interest.


1. Hunt RH, Xiao SD, Megraud F, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointest Liver Dis 2011; 20: 299-304.
2. Łaszewicz W. The results of research on Helicobacter pylori infection. Trans-Humana. Wydawnictwo Uniwersyteckie, Białystok 2004.
3. Matysiak-Budnik T, Knapik Z, Mégraud F, et al. Helicobacter pylori infection in Eastern Europe: seroprevalence in the Polish population of Lower Silesia. Am J Gastroenterol 1996; 91: 2513-5.
4. Szadkowski A, Chojnacki J, Klupińska G, et al. Clinical analysis of unsuccessful Helicobacter pylori eradication. Pol Merkuriusz Lek 2005; 17: 139-41.
5. Gisbert JP, Martín de Argila C, Redondo C, et al. New one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic. Med Clin (Barc) 1998; 110: 1-5.
6. Muszyński J, Czyżyk A, Biernacka D, et al. Combined treatment of Helicobacter pylori infection-7-day or 14-day treatment? Pol Tyg Lek 1992; 47: 641-5.
7. Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not change over the last decade, but is not good enough. Aliment Pharmacol Ther 2011; 34: 1255-68.
8. Gisbert JP, Pajares JM. Review article: Helicobacter pylori rescue regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002; 16: 1047-57.
9. Holubiuk L, Imiela J. Diet and Helicobacter pylori infection. Gastroenetrology Rev 2016; 11: 150-4.
10. Glupczynski Y, Mégraud F, Lopez-Brea M, et al. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20: 820-3.
11. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection – the Maastricht IV/Florence consensus report. Gut 2012; 61: 646-64.
12. Dzierżanowska-Fangrat K, Rozynek E, Celińska-Cedro D, et al. Antimicrobial resistance of Helicobacter pylori in Poland: a multicenter study. Int J Antimicorb Agents 2005; 26: 230-4.
13. Miwa H, Nagahara A, Kurosawa A, et al. Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? Aliment Pharmacol Ther Therapeutics 2003; 17: 1545-51.
14. Bartnik W, Celińska-Cedro D, Dzieniszewski J, et al. Guidelines from the Polish Society of Gastroenterology for the diagnosis and treatment of Helicobacter pylori infection. Gastroenterol Prakt 2014; 2: 33-41.
15. Dzieniszewski J, Jarosz M et al. Guidelines from the Polish Society of Gastroenterology for the diagnosis and treatment of Helicobacter pylori infection – consensus 2008. Gastroenterol Pol 2008; 15: 323-31.
16. Chey WD, Wong BC. Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25.
17. Sugano K, Tack J, Kuipers EJ, el al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353-67.
18. Selgrad M, Malfertheiner P. New strategies for Helicobacter pylori eradication. Curr Opin Pharmacol 2008; 8: 593-7.
19. Wenzhen Y, Yumin L, Quanin G, et al. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Intern Med 2010; 49: 1103-9.
20. Sugimoto M, Furata T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. World J Gastroenterol 2014; 20: 6400-11.
21. Avidan B, Mezler E, Keller N, et al. The effect of culture result for Helicobacter pylori on the choice of treatment following failure of initial eradication. Isr Med Assoc J 2001; 3: 163-5.
22. Selgrad M, Tammer I, Langner C, et al. Different antibiotic susceptibility between antrum and corpus of the stomach, a possible reason for treatment failure of Helicobacter pylori infection. World J Gastroenterol 2014; 20: 16245-51.
23. Paradowska A, Sieja A, Braksator M. Helicobacter pylori infection and oral cavity. Gastroenterol Pol 2010; 17: 423-6.
24. Marais A, Monteiro L, Lamouliatte H, et al. Cag negative status of Helicobacter pylori is a risk factor for failure of PPI-based triple therapies in non-ulcer dyspepsia. Gastroenterology 1998; 114: A214.
25. Suzuki T, Matsuo K, Ito H, et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med 2006; 119: 217-24.
26. Al-Medhagi AS. Eradication of Helicobacter pylori in outpatients by using triple drug therapy. Gastroenterol Pol 2004; 11: 11-4.
27. Zullo A, Hassan C, Lorenzetti R, et al. A clinical practice viewpoint: to culture or not to culture Helicobacter pylori? Dig Liver Dis 2003; 35: 357-61.
28. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with the capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomized, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905-13.
29. Miehlke S, Hansky K, Schneider-Brachert W, et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther 2006; 24: 395-403.
30. Sanchez-Delgado J, Garcia-Iglesias P, Castro-Fernandez M, et al. High-dose, ten-days esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2012; 36: 190-6.
31. Fallone CA, Chiba N, van Zanten SV, et al. The Toronto Consensus for the treatment of Helicobacter pylori Infection in adults. Gastroenterology 2016; 151: 51-69.
32. Research C for DE and. Information by Drug Class – FDA approves safety labeling changes for fluoroquinolones https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm500325.htm (accessed April 9, 2017).
33. Selgrad M, Malfertheiner P. New strategies for Helicobacter pylori eradication. Curr Opin Pharmacol 2008; 8: 593-7.

Received: 5.06.2017
Accepted: 30.06.2017
Copyright: © 2018 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
facebook linkedin twitter
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe